Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2589620 | 0.91 | PSMB8 (0.34) | PSMB8PSMB5 | |
| SCHEMBL34382 | 0.91 | TSHR (0.44) | TSHRSLC22A6PSMB8PSMB5CYP1A2 | |
| Ethylene Glycol SCHEMBL6129445 | 0.89 | TSHR (0.40) | TSHRSLC22A6PSMB8PSMB5CYP1A2 | |
| SCHEMBL290460 | 0.87 | LMNA (0.41) | TSHRSLC22A6SMN1; SMN2MEN1GAA | |
| SCHEMBL25408775 | 0.85 | TSHR (0.43) | TSHRSLC22A6SMN1; SMN2MEN1GAA | |
| SCHEMBL25408300 | 0.85 | TSHR (0.43) | TSHRSLC22A6SMN1; SMN2MEN1GAA | |
| SCHEMBL25407766 | 0.85 | TSHR (0.43) | TSHRSLC22A6SMN1; SMN2MEN1GAA | |
| SCHEMBL905403 | 0.85 | TSHR (0.43) | TSHRSLC22A6SMN1; SMN2MEN1GAA | |
| SCHEMBL336648 | 0.85 | TSHR (0.43) | TSHRSLC22A6SMN1; SMN2MEN1GAA | |
| SCHEMBL1230060 | 0.85 | TSHR (0.43) | TSHRSLC22A6SMN1; SMN2MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190263750-A1 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | THERAGENICS CORPORATION | 2019-08-29 | — | — | US | claimed |
| US-10189773-B2 | In-vivo gelling pharmaceutical pre-formulation | MEDICUS BIOSCIENCES, LLC (US) | 2019-01-29 | — | — | US | claimed |
| EP-2846847-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | Medicus Biosciences LLC (US) | 2015-03-18 | — | — | EP | claimed |
| WO-2013170195-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | MEDICUS BIOSCIENCES, LLC (US) | 2013-11-14 | — | — | WO | claimed |
| US-20130116341-A1 | IN-VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2013-05-09 | — | — | US | claimed |
| WO-2011140519-A2 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2011-11-10 | — | — | WO | claimed |
| US-20230218799-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | AQUARIAN CREDIT FUNDING LLC | 2023-07-13 | — | — | US | disclosed |
| EP-2968680-B1 | SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION | C P MEDICAL CORP (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11596710-B2 | Biocompatible hydrogel treatments for retinal detachment | AQUARIAN CREDIT FUNDING LLC | 2023-03-07 | — | — | US | disclosed |
| US-20210322785-A1 | COMPOSITIONS AND METHODS FOR TREATING WOUNDS | THERAGENICS CORPORATION | 2021-10-21 | — | — | US | disclosed |
| EP-3893785-A1 | COMPOSITIONS AND METHODS FOR TREATING WOUNDS | C.P. Medical Corporation (US) | 2021-10-20 | — | — | EP | disclosed |
| US-11083821-B2 | Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules | C.P. MEDICAL CORPORATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200316249-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | AQUARIAN CREDIT FUNDING LLC | 2020-10-08 | — | — | US | disclosed |
| WO-2014153004-A1 | SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION | MEDICUS BIOSCIENCES LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140271528-A1 | SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION | MEDICUS BIOSCIENCES LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140248231-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | MEDICUS BIOSCIENCES LLC (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2708224-A1 | Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules | Medicus Biosciences LLC (US) | 2014-03-19 | — | — | EP | disclosed |
| WO-2013170195-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | MEDICUS BIOSCIENCES, LLC (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20130116341-A1 | IN-VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2011140519-A2 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189773-B2 | In-vivo gelling pharmaceutical pre-formulation | FURIN, ARFGAP1, MGST1 | TSHR 4254/4885SLC22A6 2899/4885PSMB8 1695/4885 |
| US-20230218799-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | ALDH1A2, RB1, UACA | TSHR 1883/4885SLC22A6 4502/4885PSMB8 2250/4885 |
| US-11083821-B2 | Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules | HMGB1, HDGF, CRYAA | TSHR 2909/4885SLC22A6 1675/4885PSMB8 1033/4885 |
| US-11596710-B2 | Biocompatible hydrogel treatments for retinal detachment | ALDH1A2, RB1, UACA | TSHR 1883/4885SLC22A6 4502/4885PSMB8 2250/4885 |
| US-20190263750-A1 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | FURIN, ARFGAP1, MGST1 | TSHR 4398/4885SLC22A6 3009/4885PSMB8 1715/4885 |
| US-20130116341-A1 | IN-VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | FURIN, ARFGAP1, MGST1 | TSHR 4254/4885SLC22A6 2899/4885PSMB8 1695/4885 |
| US-20200316249-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | ALDH1A2, RB1, UACA | TSHR 1883/4885SLC22A6 4502/4885PSMB8 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.